SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-016288
Filing Date
2023-05-11
Accepted
2023-05-11 08:10:19
Documents
14
Period of Report
2023-05-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 40494
2 ex99-1.htm EX-99.1 144819
3 ex99-1_001.jpg GRAPHIC 7527
  Complete submission text file 0001493152-23-016288.txt   390581

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE prph-20230511.xsd EX-101.SCH 3239
5 XBRL LABEL FILE prph-20230511_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE prph-20230511_pre.xml EX-101.PRE 22367
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3755
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

IRS No.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-21617 | Film No.: 23908953
SIC: 2834 Pharmaceutical Preparations